Cargando…
JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis
Rhabdomyosarcoma (RMS) is a common soft-tissue sarcoma in childhood with a poor prognosis, highlighting the need for new treatment strategies. Here we identify a synergistic interaction of the second-generation histone deacetylase inhibitor (HDACI) JNJ-26481585 and common chemotherapeutic drugs (i.e...
Autores principales: | Heinicke, Ulrike, Kupka, Johanna, Fulda, Simone |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741969/ https://www.ncbi.nlm.nih.gov/pubmed/26473375 |
Ejemplares similares
-
The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction
por: He, Bin, et al.
Publicado: (2018) -
Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells
por: Haydn, Tinka, et al.
Publicado: (2017) -
Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
por: Fulda, Simone
Publicado: (2012) -
Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma
por: Graab, Ulrike, et al.
Publicado: (2015) -
Shifting the balance of mitochondrial apoptosis: therapeutic perspectives
por: Fulda, Simone
Publicado: (2012)